Biohaven Q2 EPS $(1.25) Misses $(1.18) Estimate; Cash, Cash Equivalents & Marketable Securities Of $349M
Portfolio Pulse from Benzinga Newsdesk
Biohaven (NYSE:BHVN) reported Q2 losses of $(1.25) per share, missing the analyst consensus estimate of $(1.18) by 5.93 percent. However, this is a 73 percent increase over losses of $(4.63) per share from the same period last year. The company also reported cash, cash equivalents & marketable securities of $349M.
July 31, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biohaven's Q2 earnings per share missed estimates, but losses have decreased compared to last year. The company's cash position is strong.
Biohaven's earnings per share missed the consensus estimate, which could negatively impact the stock price in the short term. However, the decrease in losses compared to the same period last year and the strong cash position could provide some buffer against a significant drop.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100